Elutia, the Gaithersburg, Maryland-based drug-eluting biomatrix company, has secured up to $26 million in funding to carry its NXT-41x product through FDA clearance and into commercial launch, without issuing new equity. The financing combines a $15 million credit facility from Avenue Capital Group, up to $11 million tied to the divestiture of its SimpliDerm business, and $8 million expected from an escrow related to its earlier BioEnvelope sale to Boston Scientific.
What NXT-41x Is Actually For
NXT-41x is an antibiotic-eluting biomatrix designed for use in plastic and reconstructive surgical procedures, built to reduce the surgical site infections that can complicate implant-based procedures like breast reconstruction. CEO Dr. Randy Mills said the company deliberately narrowed its focus to get here: “We have intentionally focused Elutia where our strengths create the greatest value for patients and shareholders. We believe we are now funded through the anticipated clearance and full commercial launch of NXT-41x, our antibiotic-eluting biomatrix for use in plastic and reconstructive surgical procedures. And we did it without an equity offering.” He pointed to a company-commissioned survey of 50 board-certified plastic and reconstructive surgeons as evidence of demand: 86% said the matrices used today increase infection risk, 96% believed Elutia’s antibiotic combination would be effective at preventing infection, and 92% said they’d help get NXT-41x approved through their hospital’s value analysis committee. Mills framed the opportunity as familiar ground for the company: “Having successfully created value with this technology in the pacemaker market, we are now applying it to a larger market with a substantially greater unmet need.”
The Regulatory and Commercial Timeline
Elutia expects FDA clearance for the related NXT-41 product in the fourth quarter of 2026, with NXT-41x clearance following in the first half of 2027 and a commercial soft launch targeted for the second half of 2027. The company reported $2.4 million in net sales and a $7.6 million net loss for the second quarter of 2026, with $19.9 million in cash on hand heading into this financing. The three funding sources layered together, the Avenue Capital credit line, the SimpliDerm sale proceeds, and the BioEnvelope escrow, are meant to bridge that roughly year-and-a-half gap between now and a real commercial ramp.
A Company That Rebuilt Itself Around This Technology
Elutia was known as Aziyo Biologics until a September 2023 rebrand, a change the company said reflected its strategic shift toward drug-eluting biomatrix technology specifically. That shift followed a difficult stretch for the company’s former orthobiologics business, which Elutia divested to Berkeley Biologics in November 2023, months after Aziyo had recalled bone graft products linked to tuberculosis infections in patients, an incident that drew congressional scrutiny at the time. Elutia’s current business, including NXT-41x, is unconnected to that divested unit, and the company has spent the two years since narrowing itself almost entirely around drug-eluting matrix technology, first in the cardiac device market with BioEnvelope, and now, with this new funding in place, in plastic and reconstructive surgery.
